Dr. Curtis has received research grants, consultant fees, and/or honoraria (less than $10,000 each) from Abbott, BMS, Crescendo, and Pfizer, and (more than $10,000 each) from Roche/Genentech, UCB, Centocor, the Consortium of Rheumatology Researchers of North America, and Amgen.
Predicting future response to certolizumab pegol in rheumatoid arthritis patients: Features at 12 weeks associated with low disease activity at 1 year†
Article first published online: 23 APR 2012
Copyright © 2012 by the American College of Rheumatology
Arthritis Care & Research
Volume 64, Issue 5, pages 658–667, May 2012
How to Cite
Curtis, J. R., Luijtens, K. and Kavanaugh, A. (2012), Predicting future response to certolizumab pegol in rheumatoid arthritis patients: Features at 12 weeks associated with low disease activity at 1 year. Arthritis Care Res, 64: 658–667. doi: 10.1002/acr.21600
ClinicalTrials.gov identifier: NCT00152386.
- Issue published online: 2 APR 2012
- Article first published online: 23 APR 2012
- Accepted manuscript online: 9 JAN 2012 10:59AM EST
- Manuscript Accepted: 3 JAN 2012
- Manuscript Received: 3 JUN 2011
- UCB Pharma
- NIH. Grant Number: AR053351
- Agency for Healthcare Research and Quality. Grant Number: R01-HS018517
Additional Supporting Information may be found in the online version of this article.
|ACR_21600_sm_SuppAppa.tif||216K||Supplementary Appendix A. CART model 4: all potential predictors (measured at baseline and at weeks 4, 6, 8, and 12) included to predict low disease activity (DAS28 ≤ 3.2) and/or ACR50 at 1 year. Variables and cut points were derived empirically using CART. Results shown are from the testing data set only since performance of the models using the training data set was generally superior.|
|ACR_21600_sm_SuppAppb.tif||178K||Supplementary Appendix B. Replication of a prediction model derived from RA patients initiating etanercept (from the TEMPO trial) (28) to the RAPID 1 population. No new statistical modeling was conducted. The predictors and cut points previously published were used and model performance evaluated using RAPID 1 data.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.